130 related articles for article (PubMed ID: 19058218)
1. How different are luminal A and basal breast cancers?
Bertucci F; Finetti P; Cervera N; Charafe-Jauffret E; Buttarelli M; Jacquemier J; Chaffanet M; Maraninchi D; Viens P; Birnbaum D
Int J Cancer; 2009 Mar; 124(6):1338-48. PubMed ID: 19058218
[TBL] [Abstract][Full Text] [Related]
2. Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms.
Sørlie T; Wang Y; Xiao C; Johnsen H; Naume B; Samaha RR; Børresen-Dale AL
BMC Genomics; 2006 May; 7():127. PubMed ID: 16729877
[TBL] [Abstract][Full Text] [Related]
3. Integrated profiling of basal and luminal breast cancers.
Adélaïde J; Finetti P; Bekhouche I; Repellini L; Geneix J; Sircoulomb F; Charafe-Jauffret E; Cervera N; Desplans J; Parzy D; Schoenmakers E; Viens P; Jacquemier J; Birnbaum D; Bertucci F; Chaffanet M
Cancer Res; 2007 Dec; 67(24):11565-75. PubMed ID: 18089785
[TBL] [Abstract][Full Text] [Related]
4. RERG (Ras-like, oestrogen-regulated, growth-inhibitor) expression in breast cancer: a marker of ER-positive luminal-like subtype.
Habashy HO; Powe DG; Glaab E; Ball G; Spiteri I; Krasnogor N; Garibaldi JM; Rakha EA; Green AR; Caldas C; Ellis IO
Breast Cancer Res Treat; 2011 Jul; 128(2):315-26. PubMed ID: 20697807
[TBL] [Abstract][Full Text] [Related]
5. Sixteen-kinase gene expression identifies luminal breast cancers with poor prognosis.
Finetti P; Cervera N; Charafe-Jauffret E; Chabannon C; Charpin C; Chaffanet M; Jacquemier J; Viens P; Birnbaum D; Bertucci F
Cancer Res; 2008 Feb; 68(3):767-76. PubMed ID: 18245477
[TBL] [Abstract][Full Text] [Related]
6. Semaphorin-plexin signalling genes associated with human breast tumourigenesis.
Gabrovska PN; Smith RA; Tiang T; Weinstein SR; Haupt LM; Griffiths LR
Gene; 2011 Dec; 489(2):63-9. PubMed ID: 21925246
[TBL] [Abstract][Full Text] [Related]
7. ESPL1 is a candidate oncogene of luminal B breast cancers.
Finetti P; Guille A; Adelaide J; Birnbaum D; Chaffanet M; Bertucci F
Breast Cancer Res Treat; 2014 Aug; 147(1):51-9. PubMed ID: 25086634
[TBL] [Abstract][Full Text] [Related]
8. An integrative hypothesis about the origin and development of sporadic and familial breast cancer subtypes.
Melchor L; Benítez J
Carcinogenesis; 2008 Aug; 29(8):1475-82. PubMed ID: 18596026
[TBL] [Abstract][Full Text] [Related]
9. Molecular analysis of hormone receptor positive (luminal) breast cancers: what have we learnt?
Loi S
Eur J Cancer; 2008 Dec; 44(18):2813-8. PubMed ID: 18990560
[TBL] [Abstract][Full Text] [Related]
10. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
[TBL] [Abstract][Full Text] [Related]
11. Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer.
Bergamaschi A; Kim YH; Wang P; Sørlie T; Hernandez-Boussard T; Lonning PE; Tibshirani R; Børresen-Dale AL; Pollack JR
Genes Chromosomes Cancer; 2006 Nov; 45(11):1033-40. PubMed ID: 16897746
[TBL] [Abstract][Full Text] [Related]
12. DNA copy number alterations and expression of relevant genes in triple-negative breast cancer.
Han W; Jung EM; Cho J; Lee JW; Hwang KT; Yang SJ; Kang JJ; Bae JY; Jeon YK; Park IA; Nicolau M; Jeffrey SS; Noh DY
Genes Chromosomes Cancer; 2008 Jun; 47(6):490-9. PubMed ID: 18314908
[TBL] [Abstract][Full Text] [Related]
13. Gene expression profiling of breast cell lines identifies potential new basal markers.
Charafe-Jauffret E; Ginestier C; Monville F; Finetti P; Adélaïde J; Cervera N; Fekairi S; Xerri L; Jacquemier J; Birnbaum D; Bertucci F
Oncogene; 2006 Apr; 25(15):2273-84. PubMed ID: 16288205
[TBL] [Abstract][Full Text] [Related]
14. First evidence supporting a potential role for the BMP/SMAD pathway in the progression of oestrogen receptor-positive breast cancer.
Helms MW; Packeisen J; August C; Schittek B; Boecker W; Brandt BH; Buerger H
J Pathol; 2005 Jul; 206(3):366-76. PubMed ID: 15892165
[TBL] [Abstract][Full Text] [Related]
15. Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers.
Bertucci F; Finetti P; Cervera N; Charafe-Jauffret E; Mamessier E; Adélaïde J; Debono S; Houvenaeghel G; Maraninchi D; Viens P; Charpin C; Jacquemier J; Birnbaum D
Cancer Res; 2006 May; 66(9):4636-44. PubMed ID: 16651414
[TBL] [Abstract][Full Text] [Related]
16. Evidence for a transcriptional signature of breast cancer.
Feng Y; Li X; Sun B; Wang Y; Zhang L; Pan X; Chen X; Wang X; Wang J; Hao X
Breast Cancer Res Treat; 2010 Jul; 122(1):65-75. PubMed ID: 19728083
[TBL] [Abstract][Full Text] [Related]
17. Exploring novel targets of basal-like breast carcinoma by comparative gene profiling and mechanism analysis.
Wu YM; Hu W; Wang Y; Wang N; Gao L; Chen ZZ; Zheng WQ
Breast Cancer Res Treat; 2013 Aug; 141(1):23-32. PubMed ID: 23933801
[TBL] [Abstract][Full Text] [Related]
18. Identification of molecular apocrine breast tumours by microarray analysis.
Farmer P; Bonnefoi H; Becette V; Tubiana-Hulin M; Fumoleau P; Larsimont D; Macgrogan G; Bergh J; Cameron D; Goldstein D; Duss S; Nicoulaz AL; Brisken C; Fiche M; Delorenzi M; Iggo R
Oncogene; 2005 Jul; 24(29):4660-71. PubMed ID: 15897907
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive molecular portraits of human breast tumours.
Cancer Genome Atlas Network
Nature; 2012 Oct; 490(7418):61-70. PubMed ID: 23000897
[TBL] [Abstract][Full Text] [Related]
20. The genomic profile of HER2-amplified breast cancers: the influence of ER status.
Marchiò C; Natrajan R; Shiu KK; Lambros MB; Rodriguez-Pinilla SM; Tan DS; Lord CJ; Hungermann D; Fenwick K; Tamber N; Mackay A; Palacios J; Sapino A; Buerger H; Ashworth A; Reis-Filho JS
J Pathol; 2008 Dec; 216(4):399-407. PubMed ID: 18810758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
